Stock Monitor: Rockwell Medical Post Earnings Reporting
LONDON, UK / ACCESSWIRE / April 10, 2018 / Active-Investors.com has just released a free research report on Impax Laboratories, Inc. (NASDAQ: IPXL). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/'symbol=IPXL as the Company's latest news hit the wire. On April 06, 2018, the Hayward-based pharmaceutical Company announced that it has launched a generic version of Estrace® Cream (estradiol vaginal cream, USP, 0.01%), indicated in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Rockwell Medical, Inc. (NASDAQ: RMTI), which also belongs to the Healthcare sector as the Company Impax Laboratories. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/'symbol=RMTI
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Impax Laboratories most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/'symbol=IPXL
Perrigo Received FDA Approval of Generic Version of Estrace® Cream in January 2018
The Company's manufacturing and development partner, Perrigo Co. PLC (NYSE: PRGO), received final approval from the US Food and Drug Administration (FDA) on January 24, 2018. The product is being marketed by Impax. According to IQVIA®, Estrace® Cream had annual US sales of approximately $469 million for the 12 months ending January 2018.
Impax Recently Launched an Authorized Generic Version of Solodyn® (Minocycline HCl) Extended-Release Tablets
On February 20, 2018, the Company launched an authorized generic version of Solodyn® (minocycline HCl) extended-release tablets, 65 mg and 115 mg. Minocycline HCl extended-release tablets, 65 mg and 115 mg, had annual US sales of approximately $148 million according to IQVIA® for the 12 months ending December 2017.
Impax to Combine with Amneal
In October 2017, Impax and Amneal Pharmaceuticals LLC entered into a definitive business combination in an all-stock transaction. As a result of the transaction, Amneal Holdings members will own 75% and Impax's shareholders will own 25% of the new company's pro-forma shares. The combined company will be named Amneal Pharmaceuticals, Inc., and will rank as the 5th largest in the United States by gross revenue and a growing, high-margin specialty franchise. The combined organization will have a diverse and differentiated pipeline with more than 300 products either filed with the FDA or in active stages of development, a foundation for international expansion with select commercial presence in the United Kingdom and Germany, and cost-efficient global manufacturing and development capabilities in all dosage forms. The proposed transaction was approved by Impax's shareholders on March 24, 2018.
About Estrace® Cream
Estrace® Cream is indicated in the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. ESTRACE vaginal cream should be used at the lowest dose possible for the treatment only as long as needed. The most common side effects include: headache, breast pain, irregular vaginal bleeding or spotting, stomach/abdominal cramps and/or bloating, nausea and vomiting, hair loss, fluid retention, vaginal yeast infection, vaginal burning, irritation, and itching. Using estrogen alone may increase the chance of getting cancer of the uterus (womb). Vaginal bleeding after menopause may be a warning sign of cancer of the uterus.
About Impax Laboratories, Inc.
Founded in 1999 and headquartered in Hayward, California, Impax Labs is an integrated specialty pharmaceutical company focused on developing, manufacturing, and marketing generic and brand pharmaceutical products.
The Company operates two divisions: Impax Generics and Impax Specialty Pharma.
About Perrigo Co. PLC
Founded in 1887 and headquartered in Dublin, Ireland, Perrigo is a leading global healthcare company that delivers value to its customers and consumers by providing Quality Affordable Healthcare Products. The Company is the world's largest manufacturer of over-the-counter (OTC) healthcare products and supplier of infant formulas for the store brand market.
Stock Performance Snapshot
April 09, 2018 - At Monday's closing bell, Impax Labs' stock declined 1.85%, ending the trading session at $18.60.
Volume traded for the day: 524.01 thousand shares.
Stock performance in the previous three-month period - up 4.06%; past twelve-month period - up 45.88%; and year-to-date - up 11.71%
After yesterday's close, Impax Labs' market cap was at $1.42 billion.
The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry. This sector was up 1.1% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
